GlassScriptPhysician profile
Terry L Morris
NPI 1215946686
$984.04
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $443 · 2021: $138 · 2022: $12.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $175.63 | 2019-2021 | |
| Novo Nordisk INC | $147.77 | 2019-2020 | |
| Glaxosmithkline, LLC. | $96.93 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $84.89 | 2019-2021 | |
| Pfizer INC. | $76.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.89 | 2019-2021 | |
| Lilly USA, LLC | $56.27 | 2020-2021 | |
| Astellas Pharma US INC | $54.48 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $54.39 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.64 | 2019-2020 | |
| Abbvie INC. | $25.33 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $24.25 | 2019-2021 | |
| Allergan, INC. | $23.73 | 2020 | |
| Daiichi Sankyo INC. | $14.27 | 2020 | |
| Circassia INC. | $13.46 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $12.94 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.